ASH 2023 | An update from LIMBER-104: zilurgisertib +/- ruxolitinib in the management of MF-associated anemia
Prithviraj Bose, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ongoing LIMBER-104 (NCT04455841) trial, evaluating the safety and efficacy of escalating doses of zilurgisertib, a potent activin receptor-like kinase-2 (ALK2) inhibitor, as monotherapy or in combination with ruxolitinib in patients with myelofibrosis (MF)-associated anemia. The promising initial results show improvements in anemia for non-transfusion-dependent patients, and the agent is well tolerated. Dr Bose outlines the drug’s mechanism of action, which involves the downregulation of hepcidin, which, in turn, promotes erythropoiesis. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: GSK, Novartis, Karyopharm, AbbVie, Pharma Essentia, Jubilant, Morphic, Incyte, BMS, CTI, Morphosys, Blueprint, Cogent, Sumitomo, Ionis
Research Funding: Kartos, Telios, Disc, Janssen, Geron, Incyte, BMS, CTI, Morphosys, Blueprint, Cogent, Sumitomo, Ionis
